The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Rheumatoid Arthritis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.
Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report:
- Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
- Rheumatoid Arthritis companies working in the treatment market are Sonoma Biotherapeutics, OncoOne, Oryn Therapeutics, Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others, are developing therapies for the Rheumatoid Arthritis treatment
- Emerging Rheumatoid Arthritis therapies in the different phases of clinical trials are- SBT-77-7101, ON104, ORTD 1, TJ003234 I-Mab, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM03, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.
- In February 2022, The FDA in the United States has agreed to review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA (adalimumab-afzb), considering it as an interchangeable biosimilar to Humira (adalimumab).
- In February 2022, Biogen Inc and Xbrane Biopharma AB have formed a commercialization and licensing agreement aimed at developing, manufacturing, and marketing Xcimzane. This preclinical monoclonal antibody serves as a potential biosimilar referencing CIMZIA (certolizumab pegol) for the treatment of rheumatoid arthritis.
- In November 2021, SinoMab BioScience Limited disclosed the completion of the targeted enrollment of 510 patients in the Phase III clinical trial for rheumatoid arthritis (RA) involving SM03 (Suciraslimab). The study findings indicated that Suciraslimab administered at a dose of 600 mg with 4 and 6 infusions respectively demonstrated both effectiveness and favorable tolerance over the 24-week treatment period compared to the placebo group.
Rheumatoid Arthritis Overview
An autoimmune disease of the joints known as rheumatoid arthritis (RA) is characterized by extraarticular involvement in addition to inflammatory arthritis. Both hands are typically affected, and morning stiffness that might continue for several hours is usual.
Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight
Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:
- SBT-77-7101: Sonoma Biotherapeutics
- ON104: OncoOne
- ORTD 1: Oryn Therapeutics
- TJ003234 I-Mab: Biopharma Co. Ltd.
- TCK-276: Teijin Pharma
- IRL-201805: Revolo Biotherapeutics
- LY3462817: Eli Lilly and Company
- Dekavil: Philogen
- AP1189: SynAct Pharma
- RC18: RemeGen
- SM03: SinoMab Bioscience
Rheumatoid Arthritis Route of Administration
Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Rheumatoid Arthritis Molecule Type
Rheumatoid Arthritis Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Rheumatoid Arthritis Pipeline Therapeutics Assessment
- Rheumatoid Arthritis Assessment by Product Type
- Rheumatoid Arthritis By Stage and Product Type
- Rheumatoid Arthritis Assessment by Route of Administration
- Rheumatoid Arthritis By Stage and Route of Administration
- Rheumatoid Arthritis Assessment by Molecule Type
- Rheumatoid Arthritis by Stage and Molecule Type
DelveInsight’s Rheumatoid Arthritis Report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies
Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:
Key companies developing therapies for Rheumatoid Arthritis are – Bristol-Myers Squibb Company, Celgene Corporation, F. Hoffmann-La, Roche AG, AbbVie Inc., Amgen Inc. Bayer AG, Boehringer Ingelheim GmbH, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Lupin Limited, Alkem Laboratories, Regeneron Pharmaceuticals, Eli Lilly and Company, Pfizer Inc, and others.
Rheumatoid Arthritis Pipeline Analysis:
The Rheumatoid Arthritis pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
- Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies
Rheumatoid Arthritis Pipeline Market Drivers
- Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of Rheumatoid Arthritis, rich emerging pipeline, acceptance of biosimilars for treatment of Rheumatoid Arthritis are some of the important factors that are fueling the Rheumatoid Arthritis Market.
Rheumatoid Arthritis Pipeline Market Barriers
- However, high cost of biologics, low adherence to the drugs, lack of daily assessment, Rheumatoid Arthritis delay in RA diagnosis and other factors are creating obstacles in the Rheumatoid Arthritis Market growth.
Scope of Rheumatoid Arthritis Pipeline Drug Insight
- Coverage: Global
- Key Rheumatoid Arthritis Companies: Sonoma Biotherapeutics, OncoOne, Oryn Therapeutics, Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, and others
- Key Rheumatoid Arthritis Therapies: SBT-77-7101, ON104, ORTD 1, TJ003234 I-Mab, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM03, and others
- Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
- Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers
Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials
Table of Contents
1. Rheumatoid Arthritis Report Introduction
2. Rheumatoid Arthritis Executive Summary
3. Rheumatoid Arthritis Overview
4. Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment
5. Rheumatoid Arthritis Pipeline Therapeutics
6. Rheumatoid Arthritis Late Stage Products (Phase II/III)
7. Rheumatoid Arthritis Mid Stage Products (Phase II)
8. Rheumatoid Arthritis Early Stage Products (Phase I)
9. Rheumatoid Arthritis Preclinical Stage Products
10. Rheumatoid Arthritis Therapeutics Assessment
11. Rheumatoid Arthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Rheumatoid Arthritis Key Companies
14. Rheumatoid Arthritis Key Products
15. Rheumatoid Arthritis Unmet Needs
16 . Rheumatoid Arthritis Market Drivers and Barriers
17. Rheumatoid Arthritis Future Perspectives and Conclusion
18. Rheumatoid Arthritis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services